Emerging Growth Patterns Driving Expansion in the Liquid Biopsy for Cancer Diagnostics Market

Advancements in cancer diagnostics are rapidly transforming the healthcare landscape, particularly through innovative techniques like liquid biopsy. This evolving market promises to revolutionize early cancer detection and monitoring by offering less invasive, real-time insights. Let's explore the projected growth, major players, emerging trends, and key segments shaping the liquid biopsy for cancer diagnostics industry.

Forecasted Market Value and Growth of the Liquid Biopsy for Cancer Diagnostics Market
The liquid biopsy for cancer diagnostics market is anticipated to expand significantly, reaching a valuation of $22.99 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 16.4%. The surge is driven by broader integration of liquid biopsy in routine cancer screening protocols, an increased emphasis on personalized cancer treatment approaches, and wider application in monitoring treatment responses. Additionally, growing investments in cancer diagnostic technologies and the expanding use of liquid biopsy for gastrointestinal and ovarian cancers are fueling this upward trend. Notable market trends include increased utilization of liquid biopsy for lung cancer diagnosis, preference for blood-based cancer screening methods, rising demand for real-time cancer tracking, diversification to multiple cancer types, and growing clinical adoption of minimally invasive diagnostic procedures.

Download a free report of the liquid biopsy for cancer diagnostics market report:
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Organizations Influencing the Liquid Biopsy for Cancer Diagnostics Market
Several prominent companies are key players in the liquid biopsy for cancer diagnostics arena. These include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Genome Diagnostics Inc., Pathway Genomics Corporation, and Angle PLC.

Strategic Acquisition Enhancing Market Capabilities
In February 2024, Veracyte Inc., a diagnostics firm based in the United States, acquired C2i Genomics Inc. for around US$70 million. This acquisition aims to strengthen Veracyte's cancer diagnostics portfolio by incorporating C2i's advanced whole-genome minimal residual disease (MRD) detection technology. This integration is expected to broaden the company's reach across the cancer care continuum, improve early detection and recurrence surveillance, and provide more in-depth clinical insights. C2i Genomics Inc., also US-based, is noted for its specialization in AI-powered whole-genome MRD testing.

View the full liquid biopsy for cancer diagnostics market report:
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Technological Innovations and Emerging Trends in Liquid Biopsy Diagnostics
The liquid biopsy sector is witnessing a surge in the adoption of cutting-edge molecular diagnostics technologies designed to accelerate testing and reduce costs. Industry leaders are investing in next-generation point-of-care (POC) molecular diagnostics solutions, including enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridization, spectral karyotyping imaging, and DNA microarrays. These advancements are increasingly integrated into POC devices for faster, more efficient cancer diagnostics. For example, in May 2023, Sensible Diagnostics, a US-based company, introduced a point-of-care PCR system capable of delivering results in just 10 minutes. The company leveraged expertise developed by Curative during the pandemic, having conducted over two million molecular POC COVID-19 tests, to develop this rapid PCR technology.

Market Segmentation and Dominant Categories in Liquid Biopsy for Cancer Diagnostics
The liquid biopsy for cancer diagnostics market is categorized into several segments for comprehensive analysis:
1) By Type: Product and Services
2) By Sample Source: Blood, Urine, and Saliva
3) By Cancer Type: Lung Cancer, Breast Cancer, Colon Cancer, and Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, and Other End-Users

Further subsegments break down the products into circulating tumor cells (CTCs) detection kits, circulating tumor DNA (ctDNA) detection kits, exosome isolation kits, and sample collection devices. Services are divided into testing, analytical, and bioinformatics services, covering the extensive scope of liquid biopsy applications in cancer diagnostics.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.